Jerald Sadoff1, Glenda Gray1, An Vandebosch1, Vicky Cárdenas1, Georgi Shukarev1, Beatriz Grinsztejn1, Paul E. Kilgore1, Carla Truyers1, Hein Fennema1, Bart Spiessens1, Kim Offergeld1, Gert C. Scheper1, Katherine A. Taylor1, Merlin L. Robb1, John J. Treanor1, Dan H. Barouch1, Jeffrey J. Stoddard1, Martin Ryser1, Mary Marovich1, Kathleen M. Neuzil1, Lawrence Corey1, Nancy Cauwenberghs1, Tamzin Tanner1, Karin Hardt1, Javier Ruiz‐Guiñazú1, Mathieu Le Gars1, Hanneke Schuitemaker1, Johan Van Hoof1, Frank Struyf1, Macaya Douoguih1
1From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, G. Shukarev, G. Scheper, M.L.G., H.S., J.V.H., M.D.); South African Research Council, Cape Town, South Africa (G.G.); Janssen Research and Development, Beerse, Belgium (A.V., C.T., H.F., B.S., K.O., M.F.R., N.C., T.T., K.H., J.R.G., F.S.); Janssen Research and Development, Spring House, PA (V.C.); Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro (B.G.); the University of Alabama at Birmingham, Birmingham (P.A.G.); the National Institute of Allergy and Infectious Diseases, Rockville (K.L.T., M.A.M.), Walter Reed Army Institute of Research, Silver Spring (M.L.R.), and the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (K.M.N.) - all in Maryland; Biomedical Advanced Research and Development Authority, Washington, DC (J.T.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston (D.H.B.); Janssen Research and Development, Raritan, NJ (J. Stoddard); and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle (L.C.).
